Article

The Impact and Management of Fibroids for Fertility An Evidence-Based Approach

Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 10 Center Drive, Building 10 CRC 1-3140, MSC 1109, Bethesda, MD 20892-1109, USA.
Obstetrics and Gynecology Clinics of North America (Impact Factor: 1.4). 12/2012; 39(4):521-33. DOI: 10.1016/j.ogc.2012.09.005
Source: PubMed

ABSTRACT Fibroids affect 35% to 77% of reproductive-age women. When selecting a treatment plan for symptomatic fibroids, the fibroid location, size, and number must be considered. Myomectomy remains the preferred method for women with fibroid-related infertility who wish to have children or maintain fertility. Currently available medical therapies reduce symptoms in the short term but may involve side effects when used long term. Initial fertility studies are encouraging but trials are needed. Recent medical advances have led to minimally invasive approaches for women with fibroid disease, but there is a strong demand for additional treatment options.

Download full-text

Full-text

Available from: James H Segars, Aug 26, 2014
0 Followers
 · 
77 Views
  • Source
    • "Uterine myomas or fibroids are the most common benign tumors of the female genital tract and are estimated to occur in about 30% of women by the age of 35 and in about 70– 80% over the age of 50 [1]. Uterine myomas form the most frequent indication for hysterectomy [2]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background and Objectives. A new two-step hysteroscopic myomectomy carried out in the office setting and without anesthesia was feasible for the excision of submucous myomas. The objective of this study was to assess whether removal of submucous myomas from the uterine cavity after hysteroscopic laser enucleation is necessary. Methods. Between June 2009 and April 2013, all outpatients with symptomatic myomatosis (bleeding, pelvic pain, and infertility) assessed ultrasonographically were eligible to participate in a prospective study. All patients underwent office hysteroscopic enucleation of submucous myomas. Enucleated myomas were left in the uterine cavity. Neither anesthesia nor antibiotic prophylaxis was used. Results. Sixty-one women (mean age: 47.3 years) were included. Regardless of hysteroscopic localization and grading, all myomas were enucleated. The mean (standard deviation, SD) diameter of the myoma as measured by the ultrasound scan was 22.6 (8.5) mm. In 29 cases (47.5%), the diameter of the resected myoma was >20 mm and in 10 cases (16.4%) >30 mm. After a mean follow-up of 68.2 (16.5) days, none of the patients showed a residual myoma inside the uterine cavity. Conclusions. The present results indicate that leaving laser-enucleated submucous myoma in the uterine cavity is a feasible and safe therapeutic option.
    BioMed Research International 05/2015; 2015:5. DOI:10.1155/2015/905204 · 2.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Uterusmyome können ein Konzeptionshindernis darstellen und auch in einer bestehenden Schwangerschaft zu Komplikationen führen. Die Arbeit gibt eine Übersicht des aktuellen Kenntnisstandes zu Ätiologie und Therapiemöglichkeiten. Das Evidenzniveau, auf dessen Basis Therapieempfehlungen gegeben werden können, ist aufgrund der unzureichenden Datenlage niedrig. Patientinnen mit unerfülltem Kinderwunsch und submukösen oder intramural/submukösen Myomen scheinen von einer Myomenukleation hinsichtlich der Schwangerschaftsrate zu profitieren. Allerdings sollte diese erst nach Durchführung einer generellen Sterilitätsdiagnostik des Paares erfolgen. Offene und laparoskopische Myomenukleationen scheinen hinsichtlich der Schwangerschaftsrate gleichwertige Verfahren darzustellen. Ein laparoskopisches Vorgehen ist mit weniger perioperativem Blutverlust und Schmerzen sowie schnellerer Rekonvaleszenz assoziiert. Ob sich eine Patientin mit Kinderwunsch, jedoch ohne Sterilitätsanamnese und bekanntem Uterusmyom vor Anstreben der Schwangerschaft einer operativen Therapie unterziehen sollte oder nicht ist unklar. Aufgrund der insgesamt unzureichenden Datenlage scheint sowohl nach hysteroskopischer Myomenukleation als auch nach offener oder laparoskopischer Myomentfernung unter entsprechender Überwachung ein vaginaler Entbindungsversuch möglich.
    Der Gynäkologe 01/2014; 47(1). DOI:10.1007/s00129-013-3203-1
  • [Show abstract] [Hide abstract]
    ABSTRACT: Laparoscopic myomectomy is regarded as the gold standard for women with symptomatic fibroids who wish to become pregnant. High-intensity focused ultrasound (HIFU or MRgFUS) ablation of uterine fibroids is also being discussed as a non-surgical, minimally invasive, therapeutic option. This review examines the available data on the impact of HIFU/MRgFUS on fertility and pregnancy, focusing particularly on potential direct side-effects of this type of intervention on ovaries, fallopian tubes and uterus and potential late effects on pregnancy and birth, based on the current literature. All pregnancies after HIFU/MRgFUS published to date (around 100 cases) were evaluated. The published case series suggest that HIFU/MRgFUS ablation has no impact on the rate of miscarriages or other obstetrical outcome parameters. Because no prospective studies exist which permit firm conclusions to be drawn on the impact of HIFU/MRgFUS on fertility and pregnancy outcome in women with symptomatic fibroids, this approach is currently only recommended for women with suspected fertility problems due to uterine fibroids who either decline surgery or who have an unacceptably high surgical risk.
    Geburtshilfe und Frauenheilkunde 02/2014; 74(2):139-145. DOI:10.1055/s-0033-1360311 · 0.96 Impact Factor
Show more